MD Anderson and Exscientia launch strategic collaboration to leverage AI in developing novel oncology treatments
The University of Texas MD Anderson Cancer Center and Exscientia plc today announced a strategic collaboration to align the drug discovery and development expertise of MD Anderson with the patient-centric artificial intelligence (AI) capabilities of Exscientia in order to advance novel small-molecule oncology therapies.
The research collaboration will utilize Exscientia’s precision medicine platform to identify novel anti-cancer...
Eyal Gottlieb, Ph.D., to join MD Anderson as Vice President for Research
The University of Texas MD Anderson Cancer Center today announced that Eyal Gottlieb, Ph.D., has been named the institution’s vice president...
MD Anderson Research Highlights: SITC 2022 Special Edition
ABSTRACTS: 374, 568, 590, 657, 659, 782
The University of Texas MD Anderson Cancer Center’s...
Response-adapted ultra-low dose radiation achieves complete response in 90% of patients with orbital indolent B-cell lymphomas
Using a novel response-adapted ultra-low dose radiation therapy strategy, researchers at The University of Texas MD Anderson Cancer Center observed a 90% complete response rate in patients with orbital indolent B-cell lymphoma. Results were presented today at the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting.
This study, led by Chelsea C. Pinnix, M.D., Ph.D., associate professor of Radiation Oncology, is the...
Allison Institute establishes internal advisory council of MD Anderson experts
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center today announced the establishment of its internal advisory...
Lung, breast and colorectal cancer tackled in latest Texas computational oncology collaboration
Three new cancer research projects have been chosen to receive seed funding as part of the program in Oncological Data and Computational Science...
MD Anderson and ARTIDIS announce strategic alliance to advance nanomechanical technology platform for optimizing cancer treatment
The University of Texas MD Anderson Cancer Center and ARTIDIS AG today announced a strategic alliance to investigate ARTIDIS technology as...
MD Anderson and Radiopharm Theranostics launch joint venture to develop novel radiopharmaceuticals
The University of Texas MD Anderson Cancer Center and Radiopharm Theranostics today announced the launch of Radiopharm Ventures, LLC, a joint...
Tumor-infiltrating B cells and plasma cells influence early-stage lung cancer biology, immunotherapy responses
Through extensive single-cell analysis, researchers at The University of Texas MD Anderson Cancer Center have created a spatial map of tumor-infiltrating...
RET inhibitor selpercatinib demonstrates durable responses in tumor-agnostic population
The highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses across multiple tumor types in...
MD Anderson and Virogin Biotech announce strategic collaboration to accelerate oncolytic virus research and development for treating advanced cancers
The University of Texas MD Anderson Cancer Center and Virogin Biotech today announced a strategic collaboration to accelerate the development...
MD Anderson and Erasca announce strategic research and development collaboration in RAS/MAPK-driven cancers
The University of Texas MD Anderson Cancer Center and Erasca, Inc. today announced a strategic research and development collaboration...
Allison Institute announces formation of scientific advisory board
The James P. Allison Institute at The University of Texas MD Anderson Cancer Center today announced the establishment of its scientific advisory...
Pralsetinib achieves tissue-agnostic benefits for patients with RET gene fusions
The highly selective RET inhibitor pralsetinib was well-tolerated and demonstrated robust, durable responses in patients with RET fusion-positive...
MD Anderson and Empyrean announce agreement to develop novel radiation therapy technologies
The University of Texas MD Anderson Cancer Center and Empyrean Medical Systems, Inc. today announced an exclusive license and joint development...
MD Anderson and TransCode Therapeutics announce strategic alliance to advance RNA therapies for oncology
The University of Texas MD Anderson Cancer Center and TransCode Therapeutics, Inc. today announced a strategic alliance to advance TransCode...
MD Anderson Research Highlights for July 27, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
MD Anderson named #1 in the nation for cancer care
The University of Texas MD Anderson Cancer Center today was named number one in the nation for cancer care in U.S. News & World Report...
MD Anderson and Obsidian Therapeutics announce FDA clearance of IND application for novel TIL therapy OBX-115
The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced Food and Drug Administration (...
Donna Hansel, M.D., Ph.D., to join MD Anderson as Division Head of Pathology and Laboratory Medicine
The University of Texas MD Anderson Cancer Center today announced that Donna Hansel, M.D., Ph.D., has been named Division Head of Pathology...
Kimberly Hoggatt Krumwiede, Ph.D., named Dean of MD Anderson’s School of Health Professions
The University of Texas MD Anderson Cancer Center today announced Kimberly Hoggatt Krumwiede, Ph.D., as dean of MD Anderson’s School of Health...
MD Anderson and Turning Point Therapeutics announce strategic alliance to advance precision cancer therapies
The University of Texas MD Anderson Cancer Center and Turning Point Therapeutics, Inc., today announced a strategic research and development...
MD Anderson, Invectys and CTMC announce strategic collaboration for CAR T cell therapy development
The University of Texas MD Anderson Cancer Center, Invectys, Inc. and the Cell Therapy Manufacturing Center (CTMC), a joint venture between...
Estimating tumor-specific total mRNA level predicts cancer outcomes
Researchers at The University of Texas MD Anderson Cancer Center have developed a new approach to quantify tumor-specific total mRNA levels...
Genetic study offers new insights into DCIS biology, progression
A new study led by the global Cancer Grand Challenges PRECISION team, including researchers from The University of Texas MD Anderson Cancer...
MD Anderson and Resilience launch joint venture to accelerate development and manufacturing of innovative cell therapies for cancer
The University of Texas MD Anderson Cancer Center and National Resilience, Inc., today announced the launch of a joint venture, the Cell Therapy...
MD Anderson Research Highlights for June 1, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
MD Anderson Research Highlights: ASCO 2022 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and...
MD Anderson Research Highlights for May 18, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
Adolescent and young adult leukemia survivors have shorter life span compared to those who have never had cancer
Researchers at The University of Texas MD Anderson Cancer Center have discovered that adolescent and young adult (AYA) cancer survivors of...
MD Anderson Research Highlights for May 4, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recently published studies in basic, translational...
MD Anderson receives over $10 million from Break Through Cancer to support collaborative research with leading cancer centers
The University of Texas MD Anderson Cancer Center was awarded more than $10 million in grants to support collaborative research teams working...
Vitamin E can boost immunotherapy responses by reinvigorating dendritic cells
Combining a retrospective analysis of clinical records with in-depth laboratory studies, researchers at The University of Texas MD Anderson...
New platform optimizes selection of combination cancer therapies
Abstract: LB119
Researchers at The University of Texas MD Anderson Cancer Center have developed a new bioinformatics platform that...
MD Anderson Research Highlights: AACR 2022 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer...
Distinct classes of fibroblasts in tumors play opposing roles, promoting or restraining pancreatic cancer growth
Researchers at The University of Texas MD Anderson Cancer Center have discovered that two distinct classes of cancer-associated fibroblasts...
MD Anderson launches James P. Allison Institute to usher in new era for immunotherapy
The University of Texas MD Anderson Cancer Center today launched the James P. Allison Institute, a visionary research and innovation...
Neal Copeland and Nancy Jenkins elected Fellows of the AACR Academy
Neal G. Copeland, Ph.D., and Nancy A. Jenkins, Ph.D., both professors of Genetics at The University of Texas MD Anderson Cancer Center...
Computational approach enables spatial mapping of single-cell data within tissues
A new computational approach developed by researchers at The University of Texas MD Anderson Cancer Center successfully combines data from...
Newly developed radio-labeled molecule enables real-time imaging of innate immune activity
Researchers at The University of Texas MD Anderson Cancer Center have developed a new radio-labeled molecule capable of selectively reacting...
MD Anderson and Yingli Pharma initiate strategic collaboration to advance development of multiple oncology programs
The University of Texas MD Anderson Cancer Center and Yingli Pharma US, Inc. today announced a strategic alliance to advance several oncology...
Nano-sized vesicles with ACE2 receptor could prevent, treat infection from current and future strains of SARS-CoV-2
Scientists at The University of Texas MD Anderson Cancer Center and Northwestern Medicine have identified natural extracellular vesicles...
MD Anderson and Eisbach Bio announce strategic collaboration to develop medicines targeting epigenetic machinery in oncology
The University of Texas MD Anderson Cancer Center and Eisbach Bio GmbH today announced a strategic research collaboration to jointly discover...